US EditionTakeda Deepens AI Drug Discovery Push with $1.7 Billion Iambic Deal
Takeda will use Iambic's AI technologies to accelerate small-molecule drug discovery in oncology and inflammation, with milestone payments potentially exceeding $1.7 billion.
- Takeda Pharmaceutical and San Diego-based Iambic Therapeutics agreed to a multi-year collaboration for oncology and gastrointestinal/inflammation drug discovery, with payments potentially totaling $1.7 billion including milestone and royalty fees.
- Seeking faster, more reliable preclinical predictions, Takeda aimed to improve early endpoint prediction with Iambic's Enchant multimodal models and automated laboratory capable of over 95% transformations and more than 1,000 molecules a week.
- A 2024 study found NeuralPLexer outperformed AlphaFold2 on structure tasks, and Iambic will train bespoke NeuralPLexer models using Revolution Medicines' structures and molecular libraries.
- Iambic's partnership momentum continued as the deal adds to five major partnerships last year and clinical progress with IAM1363's anti‑tumor activity and safety profile.
- Takeda's access will be nonexclusive but fine‑tunable, relying on infrastructure partners like Lambda and data‑infrastructure partner TetraScience, Secora said.
12 Articles
12 Articles
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
Privately held Iambic said on Monday it has entered a multi-year partnership worth more than $1.7 billion with Japan's Takeda Pharmaceutical to use artificial intelligence to help design small-molecule drugs targeting cancer and gastrointestinal diseases.
Takeda and Iambic announce $1.7bn deal to advance small molecule programmes
Takeda has entered into a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a deal that could exceed $1.7bn.The post Takeda and Iambic announce $1.7bn deal to advance small molecule programmes appeared first on Hospital Management.
pharmaceutical-technology.com
Pharmaceutical Business reviewTakeda, Iambic announce $1.7bn deal to advance small molecule programmes
Takeda has entered into a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a deal that could exceed $1.7bn.
Takeda and Iambic Forge $1.7 Billion AI-Driven Drug Discovery Pact
Takeda Pharmaceutical has entered into a multiyear collaboration with Iambic Therapeutics, a deal potentially worth over $1.7 billion, to accelerate the discovery of small molecule drugs for cancer, digestive, and immune disorders. The partnership grants Takeda access to Iambic’s AI-driven platforms, which are designed to predict protein-receptor interactions and streamline the development of new medicines. This move underscores a growing trend …
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
